There is no single official “first documented date” specifically for Vidalista CT 20 mg, because it is not an original clinically developed molecule but a branded generic formulation of tadalafil.
The active ingredient is Tadalafil, which was first approved for medical use in the early 2000s after the launch of Cialis. Since then, it has been widely used in the treatment of Erectile Dysfunction across global markets.
Vidalista CT (chewable tablet) versions appeared much later as pharmaceutical companies expanded tadalafil into more convenient formats. These Vidalista CT 20 variants were designed to help patients who prefer faster disintegration or have difficulty swallowing standard tablets.
However, unlike tadalafil itself, Vidalista CT 20 mg was not introduced through a major clinical trial publication or regulatory milestone, so it does not have a clearly recorded “first documented” scientific entry date. Instead, its existence is mainly recorded in commercial pharmaceutical catalogs, export listings, and online drug databases, which began showing chewable tadalafil products during the mid-to-late 2010s.
In summary, while tadalafil’s approval is well documented, Vidalista CT 20 mg’s “first documentation” is tied to market introduction records rather than formal medical literature, making its exact origin date variable and manufacturer-dependent.